Two Week Estradiol Exposure in Postmenopausal Women With Newly Diagnosed ER Positive Breast Cancer - Prior to Surgery: Window of Opportunity Study
Some breast cancers have estrogen receptors (ER+). The investigators know that some ER+
tumours can be cured by hormone therapy alone while other ER+ breast cancers cannot.
Currently, there is no perfect way to tell these groups apart nor do the investigators know
why some respond when others do not.
Research findings suggest that the two types of ER+ breast cancers differ in their response
to estrogen with estrogen being toxic to one type and not the other. For those tumours that
find estrogen toxic, this may explain why tumours only start to grow when estrogen levels
decrease after menopause.
The purpose of this study is to see whether a two-week treatment of estrogen equal to
pre-menopausal estrogen levels will decrease the rate at which patients' ER+ tumours grow.
This will be done by comparing the growth rate in the tissue removed during standard of care
surgery after patients have been treated with 2 weeks estrogen prior to that surgery.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society